Vermeersch, Kristina http://orcid.org/0000-0003-0762-5751
,
Belmans, Ann
Bogaerts, Kris
Gyselinck, Iwein
Cardinaels, Nina
Gabrovska, Maria
Aumann, Joseph
Demedts, Ingel K.
Corhay, Jean-Louis
Marchand, Eric
Slabbynck, Hans
Haenebalcke, Christel
Vermeersch, Stefanie
Verleden, Geert M.
Troosters, Thierry
Ninane, Vincent
Brusselle, Guy G.
Janssens, Wim
Funding for this research was provided by:
Flemish government agency for innovation by science and technology (IWT-TBM number 130233)
Article History
Received: 16 August 2019
Accepted: 9 October 2019
First Online: 29 October 2019
Ethics approval and consent to participate
: In the BACE trial, written informed consent was obtained from all participants. The study was approved by the competent authorities, the central (Commissie Medische Ethiek UZ-KU Leuven, ML10232) and local ethics committees of each participating hospital within the Consortium.
: Not applicable.
: -KV is supported as a doctoral candidate by the Flemish Government Agency for Innovation by Science and Technology (Belgium).-AB’s institute received consultancy fees from Boehringer-Ingelheim and UCB Pharma.-KB’s institute received consultancy fees from Boehringer-Ingelheim and UCB Pharma.-IG has nothing to disclose.-NC has nothing to disclose.-MG has nothing to disclose.-JA has nothing to disclose.-IKD has nothing to disclose.-JLC has received speaker and consultancy fees from Boehringer-Ingelheim, AstraZeneca, Novartis, Chiesi and GlaxoSmithKline.-EM has, within the last 5 years, received honoraria for lectures from Boehringer-Ingelheim, Chiesi and Novartis; he is a member of advisory boards for AstraZeneca, Chiesi, Boehringer-Ingelheim and Novartis.-HS has received consultancy fees from Boehringer-Ingelheim and GlaxoSmithKline.-CH has received speaker and consultancy fees from Boehringer-Ingelheim, Chiesi, AstraZeneca, GlaxoSmithKline and Novartis.-SV has nothing to disclose.-GMV has nothing to disclose.-TT is vice president of the European Respiratory Society (2018–2019). His institute received speaker and consultancy fees from Boehringer-Ingelheim, AstraZeneca and Chiesi.-VN has received speaker and consultancy fees from Boehringer-Ingelheim, AstraZeneca, Novartis, MSD, GlaxoSmithKline and Chiesi.-GB has, within the last 5 years, received honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer, Teva, UCB Pharma and Zambon; he is a member of advisory boards for AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron and Teva.-WJ is supported as a senior clinical researcher by the Fund for Scientific Research Flanders (Belgium); and has received research funding, speaker and consultancy fees from Boehringer-Ingelheim, AstraZeneca, Novartis, Chiesi and GlaxoSmithKline. WJ is co-founder of ArtIQ.